Treatment with levodopa and risk for malignant melanoma

Movement Disorders

Volumn 22, Issue 9, 2007, Pages 1252-1257

  Olsen, Jørgen H ^a   Tangerud, Karina ^a   Wermuth, Lene ^b   Frederiksen, Kirsten ^a   Friis, Søren ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b Sønderborg Hospital   (Denmark)

Author keywords

Levodopa treatment; Malignant melanoma; Nonmelanoma skin cancer; Parkinson's disease

Indexed keywords

AMANTADINE; BENSERAZIDE; BIPERIDEN; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; ENTACAPONE; LEVODOPA; ORPHENADRINE; PERGOLIDE; PRAMIPEXOLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ADJUVANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOMA; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SKIN CANCER;

ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEVODOPA; MALE; MELANOMA; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK;

EID: 34548246487     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21397     Document Type: Article

References (16)

1. Olsen JH, Friis S, Frederiksen JM, Mellernkjær L, Møller H. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
2. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol 1972;93:556-561.
3. Pfützner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 1998;37:332-336.
4. Siple JF, Scneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000;34:382-385.
5. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkisonism Relat Dis 2003;9:321-327.
6. Andersen TF, Madsen M, J̈rgensen J, Mellemkjær L, Olsen JH. The National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268.
7. Storm HH, Michelsen EV, Clemmensen IH, Phil J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997;44:535-539.
8. Fryzek JP, Hansen J, Cohen S, et al. A cohort study of Parkinson's disease and other neurodegenerative disorders in Danish welders. J Occup Environ Med 2005;47:466-472.
9. Gelb DJ, Oliver E, Oilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
10. Bailar JC, Ederer F. Significance factors for the ratio of a Poisson variable to its expectation. Biometrics 1964;20:639-643.
11. Breslow NE, Day N. Statistical methods in cancer research, Vol. 1. IARC Scientific Publications No. 32. Lyon: International Agency for Research on Cancer; 1980.
12. Møller H, Mellemkjær L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995;310:1500-1501.
13. Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics 1999;104:1042-1045.
14. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
15. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology 2002;58:581-588.
16. Jensen OM, Storm HH, Jensen HJ. Cancer registration in Denmark and the study of multiple primary cancers, 1943-1980. Natl Cancer Inst Monogr 1985;68:245-251.